Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.

ABSTRACT:

Background

Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates.

Methods

For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab/Imdevimab or Etesevimab/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy.

Results

Both groups showed a comparable spectrum of risk factors. Due to the late hospitalizatio

SUBMITTER: Pannier J 

PROVIDER: S-EPMC9956015 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature